Our member firm Kyriakides Georgopoulos Law Firm has prepared an article on on the Joint Ministerial Decision B1b, B2a,b/oik.14947/2026 (the “JMD”), which establishing the framework for partial offset of the automatic pharmaceutical clawback with eligible R&D and investment expenditures for 2026-2027.
The JMD sets out the conditions and mechanisms for this offset scheme, aiming to ease clawback burdens while strengthening innovation and investment in the healthcare sector.